AMAG Pharmaceuticals Announces Proposed Private Offering of $450 Million of Senior Notes Due 2023

WALTHAM, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals,
Inc. (Nasdaq:AMAG) today announced that it intends, subject to market
and other considerations, to offer $450 million aggregate principal
amount of Senior Notes due 2023 (the "notes").

AMAG intends to use the net proceeds from this offering to finance its
previously announced acquisition of Cord Blood Registry(R) ("CBR"), to
refinance certain existing indebtedness, to pay various fees and
expenses incurred in connection with the CBR acquisition and related
financing transactions, and for general corporate purposes.

The notes will be offered only to qualified institutional buyers
pursuant to Rule 144A under the Securities Act of 1933, as amended (the
"Securities Act") and to non-U.S. buyers in accordance with Regulation
S under the Securities Act. The notes have not been and are not
expected to be registered under the Securities Act or under any state
securities laws and, unless so registered, may not be offered or sold
in the United States or to U.S. persons except pursuant to an exemption
from, or in a transaction not subject to, the registration requirements
of the Securities Act and applicable state securities laws. This press
release does not constitute an offer to sell or the solicitation of an
offer to buy any securities, nor shall it constitute an offer,
solicitation or sale in any jurisdiction in which such offer,
solicitation or sale is unlawful.

About AMAG

As a specialty pharmaceutical company, AMAG Pharmaceuticals, Inc. uses
its business and clinical expertise to bring medical therapies and
other innovations to market that provide clear benefits and improve
people's lives. Based in Waltham, Massachusetts, AMAG has a diverse
portfolio of products in the areas of maternal health, anemia
management and cancer supportive care. In addition to continuing to
pursue opportunities to make new advancements in patients' health and
to enhance treatment accessibility, AMAG intends to continue to expand
and diversify its portfolio through the in-license or purchase of
additional pharmaceutical products or companies.

Safe Harbor Statement

This press release contains forward?looking information about AMAG
Pharmaceuticals, Inc. within the meaning of the Private Securities
Litigation Reform Act of 1995 and other federal securities laws. Any
statements contained herein which do not describe historical facts,
including but not limited to statements regarding the proposed private
offering, the anticipated use of proceeds of the offering and the
expectations regarding size and timing of completion of the offering,
are forward?looking statements which involve risks and uncertainties
that could cause actual results to differ materially from those
discussed in such forward-looking statements.

Such risks and uncertainties include, among others, the risks
identified in AMAG's filings with the U.S. Securities and Exchange
Commission (SEC), including its Annual Report on Form 10?K for the
fiscal year ended December 31, 2014, its Quarterly Report on Form 10?Q
for the quarter ended June 30, 2015 and subsequent filings with the
SEC. Any of these risks and uncertainties could materially and
adversely affect AMAG's results of operations, its profitability and
its cash flows. AMAG cautions you not to place undue reliance on any
forward-looking statements, which speak only as of the date they are